Published in Gene Therapy Weekly, July 14th, 2005
According to recent research published in the journal Clinical Cancer Research, "phosphorodiamidate morpholino oligomers (PIVIO) inhibit targeted gene expression by preventing ribosomal assembly, thereby preventing mRNA translation. AVI-4126, a PIVIO targeted against c-MYC, has been extensively characterized in multiple cancer and other disease models and is currently in human clinical trials."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.